Individuals in close proximity to care for interstitial lung disease (ILD) did not have significantly improved outcomes than those at a greater distance, based on data from more than 1600 individuals ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in ...

MORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with ...

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...

Nerandomilast, a PDE4B inhibitor, is now FDA-approved for progressive pulmonary fibrosis, offering immunomodulatory and antifibrotic effects. The FIBRONEER-ILD trial showed nerandomilast significantly ...

In patients with systemic sclerosis-related interstitial lung disease (SSc-ILD), pirfenidone plus mycophenolate mofetil combination therapy vs placebo plus mycophenolate mofetil led to no significant ...

The PFF's strategic plan includes several initiatives to make the community more inclusive of all forms of ILD, writes columnist Sam Kirton.

MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with ...

Achieved YUTREPIA ® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date ...